Business Wire

PJSC Magnitogorsk Iron and Steel Works: MMK notifies on extension of consent solicitation process

Share

PJSC Magnitogorsk Iron & Steel Works (MOEX: MAGN; LSE: MMK) notifies on the extension of the Consent Solicitation for its outstanding U.S.$500,000,000 4.375 per cent. Guaranteed Notes due 2024.

On 6 June 2022, PJSC Magnitogorsk Iron & Steel Works (the “Guarantor”) announced a consent solicitation in relation to the outstanding U.S.$500,000,000 4.375% Notes due 2024 issued by MMK International Capital DAC (the “Issuer”) (ISIN: XS1843434959 (Regulation S) / US553142AA88 (Rule 144A); Common Code: 111730628 (Regulation S) / 111730628 (Rule 144A Common code)) (the “Notes”) on the terms and subject to the conditions set forth in the Consent Solicitation Memorandum dated 6 June 2022 (the “Consent Solicitation Memorandum”). Capitalized terms used, but not defined herein, shall have the meanings given to them in the Consent Solicitation Memorandum.

The Guarantor thanks all Noteholders who have responded promptly on the demanding Consent Deadline (4 p.m. today (London time) (“Consent Deadline”). The Guarantor expects to receive further Consent instructions from Noteholders that have not yet submitted their instructions due to tight timeline. With a view to receiving the outstanding Consent Instructions necessary to achieve the Requisite Consents, the Guarantor hereby notifies the Noteholders that it has decided to extend the Consent Deadline period from 9 June 2022 (4 p.m. (London time)) to 16 June 2022 (4 p.m. (London time)) (the “New Consent Deadline”).

Amendments to the Consent Solicitation are limited to the New Consent Deadline, as outlined above. All other terms of the Consent Solicitation will remain the same.

The Guarantor strongly encourages those Noteholders that have not yet participated in the Consent Solicitation to liaise at their earliest convenience with its Investor Relations department and/or Rybalkin, Gortsunyan, Dyakin and Partners Advocates Bureau (“RGD”) directly to obtain a copy of the Consent Solicitation Memorandum and to discuss other related matters. Noteholders who have already delivered Consent Instructions in the Consent Solicitation will be deemed to have consented to the Amendments unless they validly revoke their Consents prior to the earlier of the Effective time and the New Consent Deadline.

All documentation relating to the Consent Solicitation, together with any updates, will be available upon request to RGD at MMKconsentsolicitation2022@rgd.legal. In your communique, please also confirm the aggregate notional amount of the Notes that you hold and the location of the depository.

Noteholders may contact RGD via email at MMKconsentsolicitation2022@rgd.legal if they require assistance.

Should the Noteholders have any additional questions, please contact with the Guarantor’s Investor Relations department via email at: ir@mmk.ru.

ISIN:US5591892048
Category Code:MSCM
TIDM:MMK
LEI Code:253400XSJ4C01YMCXG44
Sequence No.:

167356

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Relations Department
Veronika Kryachko
+7 (3519) 25-75-01
kryachko.vs@mmk.ru

Communications Department
Dmitriy Kuchumov
+7 (499) 238-26-13
kuchumov.do@mmk.ru

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

French Defense Innovation Agency Investigates the Use of DNA Script’s SYNTAX System to Synthesize Custom qPCR Probes for On-demand Detection of Biothreats28.6.2022 12:00:00 CEST | Press release

DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, has announced the first successful qPCR assays using primers and probes synthesized by a customer via enzymatic synthesis using the company’s SYNTAX System DNA printer. This success was achieved as part of a contract with the French Defense Innovation Agency, in liaison with the French Armament General Directorate (DGA), first announced in January 2021. The partnership leverages the SYNTAX System to produce high-quality DNA primers and probes to rapidly develop qPCR assays for infectious disease detection. Based on these results, the collaboration has been extended to further test EDS primers and probes for qPCR assay development, giving the DGA access to new versions of synthesis and labeling technologies that the company commercially develops. This market’s applications in biodefense are a strategic focus contributing to the sovereign production of biological assays for the French Ministry for the Armed Fo

Aleph Farms Hires Chief of Regulatory Affairs Ahead of Global Commercialization28.6.2022 12:00:00 CEST | Press release

Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, today announced the addition of Yifat Gavriel as Chief of Regulatory Affairs and Quality Assurance. In this position, Gavriel will play a critical role in the introduction of Aleph Farms’ novel products into global markets. The establishment of a regulatory approval process for cultivated meat is underway in many countries around the world, with the Singapore Food Agency the first to approve it as an ingredient in 2020. “Yifat brings valuable expertise to the team, and we are delighted to have her join us at such a critical juncture in our journey to market,” said Didier Toubia, CEO and co-founder of Aleph Farms. “In our work with regulatory agencies around the world, we have seen firsthand how they encourage innovation and have been willing to continue transparent dialogues with us and the wider cultivated meat industry. The next 6-12 months will prove critical as we wo

MRM Health Starts Clinical Trial with Next-Generation Optimized Consortium Therapeutic MH002 in Pouchitis28.6.2022 11:23:00 CEST | Press release

MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they have received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium to start a Phase 2 trial with the novel next-generation optimized consortium therapy, MH002, in patients with Pouchitis. MH002 is the first, rationally designed, consortium therapy, in which key disease-driving mechanisms guide therapeutic microbial strain selection, to enter clinical development in Pouchitis. Pouchitis (inflammation of the surgically constructed pouch after colectomy) is the most prominent complication after surgical removal of the large bowel (colectomy) that is performed as a last resort treatment in Ulcerative Colitis (UC). Pouchitis occurs in up to 50% of these patients within 1-2 years after surgery. Disease mechanisms include impaired gut wall barrier function linked to gut microbiome dysbiosis, translocatio

L&T Technology Services Inaugurates Engineering Design Centre in France28.6.2022 10:00:00 CEST | Press release

L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global pure-play engineering services company, inaugurated its Engineering Design Centre (EDC) in Toulouse, France, to initially cater to the new age digital requirements of the global aerospace and defence sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220627005829/en/ Seen in the picture during the Ribbon Cutting Ceremony (from left to right): Deepanshu Khurana, Embassy of India; Véronique Canceill, Airbus; Amit Chadha, LTTS; Patrice Vassal, Invest in Toulouse; Marie-Eve Rigollet, Airbus (Photo: Business Wire) The EDC will initially focus on developing cutting-edge solutions for the aerospace and defence industries and LTTS will work with major OEMs in the region as an engineering partner. The center will specialize in end-to-end solutions for aerospace design & manufacturing, with a workforce of LTTS engineers having proven expertise in digital e

Turkish Medical Team Separates Conjoined Twins in 9 Hours, Breaking World Record28.6.2022 09:43:00 CEST | Press release

A Turkish medical team has successfully separated conjoined twins shortly after birth by employing a range of innovative techniques, including virtual simulations and 3D modeling. Carried out at Istanbul’s Acibadem Hospital, the successful procedure set a new world record for the fastest-ever operation of its kind. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220627005307/en/ Turkish Medical Team Separates Conjoined Twins in 9 Hours, Breaking World Record (Photo: Business Wire) “Thanks to our team of dedicated professionals, we were able to separate the twins in a well-planned surgical procedure that took about nine hours,” Prof. Mehmet Veli Karaaltin, who supervised the operation, says. He is an M.D. specialized in aesthetic, plastic and reconstructive surgery. As a result of the procedure, the twins, who were born conjoined at the breastbone but has two hearts, were both able to survive on their own. Born in Algeria, the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom